|
1
|
Lambrechts A, Van Troys M and Ampe C: The
actin cytoskeleton in normal and pathological cell motility. Int J
Biochem Cell Biol. 36:1890–1909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jeon M, You D, Bae SY, Kim SW, Nam SJ, Kim
HH, Kim S and Lee JE: Dimerization of EGFR and HER2 induces breast
cancer cell motility through STAT1-dependent ACTA2 induction.
Oncotarget. 8:50570–50581. 2016.PubMed/NCBI
|
|
3
|
Kim S, Lee J, Oh SJ, Nam SJ and Lee JE:
Differential effect of EGFR inhibitors on tamoxifen-resistant
breast cancer cells. Oncol Rep. 34:1613–1619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee HW, Park YM, Lee SJ, Cho HJ, Kim DH,
Lee JI, Kang MS, Seol HJ, Shim YM, Nam DH, et al: Alpha-smooth
muscle actin (ACTA2) is required for metastatic potential of human
lung adenocarcinoma. Clin Cancer Res. 19:5879–5889. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sinn M, Denkert C, Striefler JK, Pelzer U,
Stieler JM, Bahra M, Lohneis P, Dorken B, Oettle H, Riess H and
Sinn BV: α-Smooth muscle actin expression and desmoplastic stromal
reaction in pancreatic cancer: results from the CONKO-001 study. Br
J Cancer. 111:1917–1923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsujino T, Seshimo I, Yamamoto H, Ngan CY,
Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M:
Stromal myofibroblasts predict disease recurrence for colorectal
cancer. Clin Cancer Res. 13:2082–2090. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aoki H, Ohnishi H, Hama K, Shinozaki S,
Kita H, Osawa H, Yamamoto H, Sato K, Tamada K and Sugano K:
Cyclooxygenase-2 is required for activated pancreatic stellate
cells to respond to proinflammatory cytokines. Am J Physiol Cell
Physiol. 292:C259–C268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim MJ, Ahn J, Yi JY, Kim MH, Son AR, Lee
SL, Lim DS, Kim SS, Kang MA, Han Y, et al: Induction of galectin-1
by TGF-β1 accelerates fibrosis through enhancing nuclear retention
of Smad2. Exp Cell Res. 326:125–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davidoff AM, Humphrey PA, Iglehart JD and
Marks JR: Genetic basis for p53 overexpression in human breast
cancer. Proc Natl Acad Sci USA. 88:5006–5010. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sugrue MM, Shin DY, Lee SW and Aaronson
SA: Wild-type p53 triggers a rapid senescence program in human
tumor cells lacking functional p53. Proc Natl Acad Sci USA.
94:9648–9653. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Royds JA and Iacopetta B: p53 and disease:
When the guardian angel fails. Cell Death Differ. 13:1017–1026.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sur S, Pagliarini R, Bunz F, Rago C, Diaz
LA Jr, Kinzler KW, Vogelstein B and Papadopoulos N: A panel of
isogenic human cancer cells suggests a therapeutic approach for
cancers with inactivated p53. Proc Natl Acad Sci USA.
106:3964–3969. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woods DB and Vousden KH: Regulation of p53
function. Exp Cell Res. 264:56–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gasco M, Shami S and Crook T: The p53
pathway in breast cancer. Breast Cancer Res. 4:70–76. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi HK, Yang JW, Roh SH, Han CY and Kang
KW: Induction of multidrug resistance associated protein 2 in
tamoxifen-resistant breast cancer cells. Endocr Relat Cancer.
14:293–303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
You D, Jung SP, Jeong Y, Bae SY, Lee JE
and Kim S: Fibronectin expression is upregulated by PI-3K/Akt
activation in tamoxifen-resistant breast cancer cells. BMB Rep.
50:615–620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gyorffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, et
al: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abbas T, White D, Hui L, Yoshida K, Foster
DA and Bargonetti J: Inhibition of human p53 basal transcription by
down-regulation of protein kinase Cdelta. J Biol Chem.
279:9970–9977. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim S, Han J, Kim NY, Lee SK, Cho DH, Choi
MY, Kim JS, Kim JH, Choe JH, Nam SJ, et al: Effect of berberine on
p53 expression by TPA in breast cancer cells. Oncol Rep.
27:210–215. 2012.PubMed/NCBI
|
|
23
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ding L, Zhang Z, Shang D, Cheng J, Yuan H,
Wu Y, Song X and Jiang H: α-Smooth muscle actin-positive
myofibroblasts, in association with epithelial-mesenchymal
transition and lymphogenesis, is a critical prognostic parameter in
patients with oral tongue squamous cell carcinoma. J Oral Pathol
Med. 43:335–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han J, Kim S, Yang JH, Nam SJ and Lee JE:
TPA-induced p21 expression augments G2/M arrest through a
p53-independent mechanism in human breast cancer cells. Oncol Rep.
27:517–522. 2012.PubMed/NCBI
|
|
28
|
Chen R, Zhang Z, Xue Z, Wang L, Fu M, Lu
Y, Bai L, Zhang D and Fan Z: Focal adhesion kinase (FAK) siRNA
inhibits human hypertrophic scar by suppressing integrin alpha,
TGF-β and α-SMA. Cell Biol Int. 38:803–808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Butler P, Wang Y, Hu Y, Han DC,
Usami S, Guan JL and Chien S: The role of the dynamics of focal
adhesion kinase in the mechanotaxis of endothelial cells. Proc Natl
Acad Sci U S A. 99:3546–3551. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Enge M, Bao W, Hedstrom E, Jackson SP,
Moumen A and Selivanova G: MDM2-dependent downregulation of p21 and
hnRNP K provides a switch between apoptosis and growth arrest
induced by pharmacologically activated p53. Cancer Cell.
15:171–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menendez D, Inga A and Resnick MA: The
expanding universe of p53 targets. Nat Rev Cancer. 9:724–737. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
You D, Jung SP, Jeong Y, Bae SY and Kim S:
Wild-type p53 controls the level of fibronectin expression in
breast cancer cells. Oncol Rep. 38:2551–2557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jeong Y, You D, Kang HG, Yu J, Kim SW, Nam
SJ, Lee JE and Kim S: Berberine suppresses fibronectin expression
through inhibition of c-jun phosphorylation in breast cancer cells.
J Breast Cancer. 21:21–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu WS, Heinrichs S, Xu D, Garrison SP,
Zambetti GP, Adams JM and Look AT: Slug antagonizes p53-mediated
apoptosis of hematopoietic progenitors by repressing puma.
Cell. 123:641–653. 2005. View Article : Google Scholar : PubMed/NCBI
|
